Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0316798 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Monica G Ferrini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America. Hauptthemen laut MEDLINE: Nitric Oxide Synthase Type III, Dietary Supplements, Nitric Oxide, Cyclic GMP. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, National Institute on Minority Health and Health Disparities, Peter A. Morton Foundation.
Abstract (Originalsprache)
The nutraceutical COMP-4 –consisting of L-citrulline, ginger extract, and herbal components Paullinia cupana and muira puama–has been shown previously to stimulate the production of nitric oxide (NO) in a variety of tissue types. We hypothesized that COMP-4 may have a protective, stimulatory effect on the vascular endothelial cell. Human umbilical arterial endothelial cells were incubated for 24 hours with or without COMP-4 and, to replicate impairment of endothelial function, co-incubated with or without H 2 O 2 . NO intracellular content, nitrite formation and cGMP content in culture media, nitric oxide synthase (NOS) isoforms and mRNA content, pro-inflammatory cytokines, and PAI-1 expression and activity were measured. COMP-4 increased endothelial cell production of NO and cGMP and the expression of both endothelial NOS (eNOS) and inducible NOS (iNOS), in tandem with a reduction in cytokine expression and activity of PAI-1. Co-incubation of COMP-4 with H 2 O 2 reversed detrimental effects of H 2 O 2 on endothelial function, evidenced by improvement in NO availability and abrogation of the pro-inflammatory milieu. These results suggest that COMP-4 exerts a stimulatory effect on endothelial cell eNOS and iNOS to increase NO bioavailability, leading to a reduction in pro-inflammatory cytokines, particularly the prothrombotic PAI-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health and Life Sciences, Charles R. Drew University of Medicine and Science, Los Angeles, California, United States of America.
- Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
ORCID-Profile: Revecca Millán, Sriram V Eleswarapu
Förderung
- NIMHD NIH HHS
- National Institute on Minority Health and Health Disparities
- Peter A. Morton Foundation
Zitieren
APA
Ferrini, M. G., Abraham, A., Millán, R., Graciano, L., Eleswarapu, S. V., & Rajfer, J. (2025). Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0316798
Vancouver
Ferrini MG, Abraham A, Millán R, Graciano L, Eleswarapu SV, Rajfer J. Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway. PLOS ONE. 2025. doi:10.1371/journal.pone.0316798
BibTeX
@article{Ferrini2025,
author = {Ferrini, Monica G and Abraham, Andrea and Millán, Revecca and Graciano, Leslie and Eleswarapu, Sriram V and Rajfer, Jacob},
title = {Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0316798}
}
EUVIMED